Medical Care

Global Peripheral T-cell lymphoma Therapy Market Research Report 2025

The global market for Peripheral T-cell lymphoma Therapy was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Peripheral T-cell lymphoma Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peripheral T-cell lymphoma Therapy.
The Peripheral T-cell lymphoma Therapy market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Peripheral T-cell lymphoma Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Peripheral T-cell lymphoma Therapy companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Antengene
Genor BioPharma Co., Ltd.
Hospira (Pfizer Inc.)
Dizal Pharma
Bristol-Myers Squibb Company
Sigma-Tau Pharmaceuticals, Inc.
Pacira Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc.
Celgene Corporation
Eisai Co., Ltd.
Leadiant Biosciences
Merck
Genmab AS
HUYABIO International
Segment by Type
Chidamide
Selinexor
Other
Segment by Application
Hospitals
Clinics
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peripheral T-cell lymphoma Therapy company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Chidamide
1.2.3 Selinexor
1.2.4 Other
1.3 Market by Application
1.3.1 Global Peripheral T-cell lymphoma Therapy Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Clinics
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peripheral T-cell lymphoma Therapy Market Perspective (2020-2031)
2.2 Global Peripheral T-cell lymphoma Therapy Growth Trends by Region
2.2.1 Global Peripheral T-cell lymphoma Therapy Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Peripheral T-cell lymphoma Therapy Historic Market Size by Region (2020-2025)
2.2.3 Peripheral T-cell lymphoma Therapy Forecasted Market Size by Region (2026-2031)
2.3 Peripheral T-cell lymphoma Therapy Market Dynamics
2.3.1 Peripheral T-cell lymphoma Therapy Industry Trends
2.3.2 Peripheral T-cell lymphoma Therapy Market Drivers
2.3.3 Peripheral T-cell lymphoma Therapy Market Challenges
2.3.4 Peripheral T-cell lymphoma Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peripheral T-cell lymphoma Therapy Players by Revenue
3.1.1 Global Top Peripheral T-cell lymphoma Therapy Players by Revenue (2020-2025)
3.1.2 Global Peripheral T-cell lymphoma Therapy Revenue Market Share by Players (2020-2025)
3.2 Global Peripheral T-cell lymphoma Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Peripheral T-cell lymphoma Therapy Revenue
3.4 Global Peripheral T-cell lymphoma Therapy Market Concentration Ratio
3.4.1 Global Peripheral T-cell lymphoma Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peripheral T-cell lymphoma Therapy Revenue in 2024
3.5 Global Key Players of Peripheral T-cell lymphoma Therapy Head office and Area Served
3.6 Global Key Players of Peripheral T-cell lymphoma Therapy, Product and Application
3.7 Global Key Players of Peripheral T-cell lymphoma Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Peripheral T-cell lymphoma Therapy Breakdown Data by Type
4.1 Global Peripheral T-cell lymphoma Therapy Historic Market Size by Type (2020-2025)
4.2 Global Peripheral T-cell lymphoma Therapy Forecasted Market Size by Type (2026-2031)
5 Peripheral T-cell lymphoma Therapy Breakdown Data by Application
5.1 Global Peripheral T-cell lymphoma Therapy Historic Market Size by Application (2020-2025)
5.2 Global Peripheral T-cell lymphoma Therapy Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Peripheral T-cell lymphoma Therapy Market Size (2020-2031)
6.2 North America Peripheral T-cell lymphoma Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Peripheral T-cell lymphoma Therapy Market Size by Country (2020-2025)
6.4 North America Peripheral T-cell lymphoma Therapy Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peripheral T-cell lymphoma Therapy Market Size (2020-2031)
7.2 Europe Peripheral T-cell lymphoma Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Peripheral T-cell lymphoma Therapy Market Size by Country (2020-2025)
7.4 Europe Peripheral T-cell lymphoma Therapy Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size (2020-2031)
8.2 Asia-Pacific Peripheral T-cell lymphoma Therapy Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size by Region (2020-2025)
8.4 Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peripheral T-cell lymphoma Therapy Market Size (2020-2031)
9.2 Latin America Peripheral T-cell lymphoma Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Peripheral T-cell lymphoma Therapy Market Size by Country (2020-2025)
9.4 Latin America Peripheral T-cell lymphoma Therapy Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size (2020-2031)
10.2 Middle East & Africa Peripheral T-cell lymphoma Therapy Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size by Country (2020-2025)
10.4 Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Antengene
11.1.1 Antengene Company Details
11.1.2 Antengene Business Overview
11.1.3 Antengene Peripheral T-cell lymphoma Therapy Introduction
11.1.4 Antengene Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025)
11.1.5 Antengene Recent Development
11.2 Genor BioPharma Co., Ltd.
11.2.1 Genor BioPharma Co., Ltd. Company Details
11.2.2 Genor BioPharma Co., Ltd. Business Overview
11.2.3 Genor BioPharma Co., Ltd. Peripheral T-cell lymphoma Therapy Introduction
11.2.4 Genor BioPharma Co., Ltd. Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025)
11.2.5 Genor BioPharma Co., Ltd. Recent Development
11.3 Hospira (Pfizer Inc.)
11.3.1 Hospira (Pfizer Inc.) Company Details
11.3.2 Hospira (Pfizer Inc.) Business Overview
11.3.3 Hospira (Pfizer Inc.) Peripheral T-cell lymphoma Therapy Introduction
11.3.4 Hospira (Pfizer Inc.) Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025)
11.3.5 Hospira (Pfizer Inc.) Recent Development
11.4 Dizal Pharma
11.4.1 Dizal Pharma Company Details
11.4.2 Dizal Pharma Business Overview
11.4.3 Dizal Pharma Peripheral T-cell lymphoma Therapy Introduction
11.4.4 Dizal Pharma Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025)
11.4.5 Dizal Pharma Recent Development
11.5 Bristol-Myers Squibb Company
11.5.1 Bristol-Myers Squibb Company Company Details
11.5.2 Bristol-Myers Squibb Company Business Overview
11.5.3 Bristol-Myers Squibb Company Peripheral T-cell lymphoma Therapy Introduction
11.5.4 Bristol-Myers Squibb Company Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025)
11.5.5 Bristol-Myers Squibb Company Recent Development
11.6 Sigma-Tau Pharmaceuticals, Inc.
11.6.1 Sigma-Tau Pharmaceuticals, Inc. Company Details
11.6.2 Sigma-Tau Pharmaceuticals, Inc. Business Overview
11.6.3 Sigma-Tau Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Introduction
11.6.4 Sigma-Tau Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025)
11.6.5 Sigma-Tau Pharmaceuticals, Inc. Recent Development
11.7 Pacira Pharmaceuticals, Inc.
11.7.1 Pacira Pharmaceuticals, Inc. Company Details
11.7.2 Pacira Pharmaceuticals, Inc. Business Overview
11.7.3 Pacira Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Introduction
11.7.4 Pacira Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025)
11.7.5 Pacira Pharmaceuticals, Inc. Recent Development
11.8 Spectrum Pharmaceuticals, Inc.
11.8.1 Spectrum Pharmaceuticals, Inc. Company Details
11.8.2 Spectrum Pharmaceuticals, Inc. Business Overview
11.8.3 Spectrum Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Introduction
11.8.4 Spectrum Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025)
11.8.5 Spectrum Pharmaceuticals, Inc. Recent Development
11.9 Celgene Corporation
11.9.1 Celgene Corporation Company Details
11.9.2 Celgene Corporation Business Overview
11.9.3 Celgene Corporation Peripheral T-cell lymphoma Therapy Introduction
11.9.4 Celgene Corporation Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025)
11.9.5 Celgene Corporation Recent Development
11.10 Eisai Co., Ltd.
11.10.1 Eisai Co., Ltd. Company Details
11.10.2 Eisai Co., Ltd. Business Overview
11.10.3 Eisai Co., Ltd. Peripheral T-cell lymphoma Therapy Introduction
11.10.4 Eisai Co., Ltd. Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025)
11.10.5 Eisai Co., Ltd. Recent Development
11.11 Leadiant Biosciences
11.11.1 Leadiant Biosciences Company Details
11.11.2 Leadiant Biosciences Business Overview
11.11.3 Leadiant Biosciences Peripheral T-cell lymphoma Therapy Introduction
11.11.4 Leadiant Biosciences Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025)
11.11.5 Leadiant Biosciences Recent Development
11.12 Merck
11.12.1 Merck Company Details
11.12.2 Merck Business Overview
11.12.3 Merck Peripheral T-cell lymphoma Therapy Introduction
11.12.4 Merck Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025)
11.12.5 Merck Recent Development
11.13 Genmab AS
11.13.1 Genmab AS Company Details
11.13.2 Genmab AS Business Overview
11.13.3 Genmab AS Peripheral T-cell lymphoma Therapy Introduction
11.13.4 Genmab AS Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025)
11.13.5 Genmab AS Recent Development
11.14 HUYABIO International
11.14.1 HUYABIO International Company Details
11.14.2 HUYABIO International Business Overview
11.14.3 HUYABIO International Peripheral T-cell lymphoma Therapy Introduction
11.14.4 HUYABIO International Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025)
11.14.5 HUYABIO International Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Chidamide
Table 3. Key Players of Selinexor
Table 4. Key Players of Other
Table 5. Global Peripheral T-cell lymphoma Therapy Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Peripheral T-cell lymphoma Therapy Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Peripheral T-cell lymphoma Therapy Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Peripheral T-cell lymphoma Therapy Market Share by Region (2020-2025)
Table 9. Global Peripheral T-cell lymphoma Therapy Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Peripheral T-cell lymphoma Therapy Market Share by Region (2026-2031)
Table 11. Peripheral T-cell lymphoma Therapy Market Trends
Table 12. Peripheral T-cell lymphoma Therapy Market Drivers
Table 13. Peripheral T-cell lymphoma Therapy Market Challenges
Table 14. Peripheral T-cell lymphoma Therapy Market Restraints
Table 15. Global Peripheral T-cell lymphoma Therapy Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Peripheral T-cell lymphoma Therapy Market Share by Players (2020-2025)
Table 17. Global Top Peripheral T-cell lymphoma Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripheral T-cell lymphoma Therapy as of 2024)
Table 18. Ranking of Global Top Peripheral T-cell lymphoma Therapy Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Peripheral T-cell lymphoma Therapy Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Peripheral T-cell lymphoma Therapy, Headquarters and Area Served
Table 21. Global Key Players of Peripheral T-cell lymphoma Therapy, Product and Application
Table 22. Global Key Players of Peripheral T-cell lymphoma Therapy, Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Peripheral T-cell lymphoma Therapy Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Peripheral T-cell lymphoma Therapy Revenue Market Share by Type (2020-2025)
Table 26. Global Peripheral T-cell lymphoma Therapy Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Peripheral T-cell lymphoma Therapy Revenue Market Share by Type (2026-2031)
Table 28. Global Peripheral T-cell lymphoma Therapy Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Peripheral T-cell lymphoma Therapy Revenue Market Share by Application (2020-2025)
Table 30. Global Peripheral T-cell lymphoma Therapy Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Peripheral T-cell lymphoma Therapy Revenue Market Share by Application (2026-2031)
Table 32. North America Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Peripheral T-cell lymphoma Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Peripheral T-cell lymphoma Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Peripheral T-cell lymphoma Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Peripheral T-cell lymphoma Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Peripheral T-cell lymphoma Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Peripheral T-cell lymphoma Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size by Country (2026-2031) & (US$ Million)
Table 47. Antengene Company Details
Table 48. Antengene Business Overview
Table 49. Antengene Peripheral T-cell lymphoma Therapy Product
Table 50. Antengene Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025) & (US$ Million)
Table 51. Antengene Recent Development
Table 52. Genor BioPharma Co., Ltd. Company Details
Table 53. Genor BioPharma Co., Ltd. Business Overview
Table 54. Genor BioPharma Co., Ltd. Peripheral T-cell lymphoma Therapy Product
Table 55. Genor BioPharma Co., Ltd. Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025) & (US$ Million)
Table 56. Genor BioPharma Co., Ltd. Recent Development
Table 57. Hospira (Pfizer Inc.) Company Details
Table 58. Hospira (Pfizer Inc.) Business Overview
Table 59. Hospira (Pfizer Inc.) Peripheral T-cell lymphoma Therapy Product
Table 60. Hospira (Pfizer Inc.) Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025) & (US$ Million)
Table 61. Hospira (Pfizer Inc.) Recent Development
Table 62. Dizal Pharma Company Details
Table 63. Dizal Pharma Business Overview
Table 64. Dizal Pharma Peripheral T-cell lymphoma Therapy Product
Table 65. Dizal Pharma Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025) & (US$ Million)
Table 66. Dizal Pharma Recent Development
Table 67. Bristol-Myers Squibb Company Company Details
Table 68. Bristol-Myers Squibb Company Business Overview
Table 69. Bristol-Myers Squibb Company Peripheral T-cell lymphoma Therapy Product
Table 70. Bristol-Myers Squibb Company Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025) & (US$ Million)
Table 71. Bristol-Myers Squibb Company Recent Development
Table 72. Sigma-Tau Pharmaceuticals, Inc. Company Details
Table 73. Sigma-Tau Pharmaceuticals, Inc. Business Overview
Table 74. Sigma-Tau Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product
Table 75. Sigma-Tau Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025) & (US$ Million)
Table 76. Sigma-Tau Pharmaceuticals, Inc. Recent Development
Table 77. Pacira Pharmaceuticals, Inc. Company Details
Table 78. Pacira Pharmaceuticals, Inc. Business Overview
Table 79. Pacira Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product
Table 80. Pacira Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025) & (US$ Million)
Table 81. Pacira Pharmaceuticals, Inc. Recent Development
Table 82. Spectrum Pharmaceuticals, Inc. Company Details
Table 83. Spectrum Pharmaceuticals, Inc. Business Overview
Table 84. Spectrum Pharmaceuticals, Inc. Peripheral T-cell lymphoma Therapy Product
Table 85. Spectrum Pharmaceuticals, Inc. Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025) & (US$ Million)
Table 86. Spectrum Pharmaceuticals, Inc. Recent Development
Table 87. Celgene Corporation Company Details
Table 88. Celgene Corporation Business Overview
Table 89. Celgene Corporation Peripheral T-cell lymphoma Therapy Product
Table 90. Celgene Corporation Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025) & (US$ Million)
Table 91. Celgene Corporation Recent Development
Table 92. Eisai Co., Ltd. Company Details
Table 93. Eisai Co., Ltd. Business Overview
Table 94. Eisai Co., Ltd. Peripheral T-cell lymphoma Therapy Product
Table 95. Eisai Co., Ltd. Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025) & (US$ Million)
Table 96. Eisai Co., Ltd. Recent Development
Table 97. Leadiant Biosciences Company Details
Table 98. Leadiant Biosciences Business Overview
Table 99. Leadiant Biosciences Peripheral T-cell lymphoma Therapy Product
Table 100. Leadiant Biosciences Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025) & (US$ Million)
Table 101. Leadiant Biosciences Recent Development
Table 102. Merck Company Details
Table 103. Merck Business Overview
Table 104. Merck Peripheral T-cell lymphoma Therapy Product
Table 105. Merck Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025) & (US$ Million)
Table 106. Merck Recent Development
Table 107. Genmab AS Company Details
Table 108. Genmab AS Business Overview
Table 109. Genmab AS Peripheral T-cell lymphoma Therapy Product
Table 110. Genmab AS Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025) & (US$ Million)
Table 111. Genmab AS Recent Development
Table 112. HUYABIO International Company Details
Table 113. HUYABIO International Business Overview
Table 114. HUYABIO International Peripheral T-cell lymphoma Therapy Product
Table 115. HUYABIO International Revenue in Peripheral T-cell lymphoma Therapy Business (2020-2025) & (US$ Million)
Table 116. HUYABIO International Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
Table 120. Authors List of This Report


List of Figures
Figure 1. Peripheral T-cell lymphoma Therapy Picture
Figure 2. Global Peripheral T-cell lymphoma Therapy Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Peripheral T-cell lymphoma Therapy Market Share by Type: 2024 VS 2031
Figure 4. Chidamide Features
Figure 5. Selinexor Features
Figure 6. Other Features
Figure 7. Global Peripheral T-cell lymphoma Therapy Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Peripheral T-cell lymphoma Therapy Market Share by Application: 2024 VS 2031
Figure 9. Hospitals Case Studies
Figure 10. Clinics Case Studies
Figure 11. Peripheral T-cell lymphoma Therapy Report Years Considered
Figure 12. Global Peripheral T-cell lymphoma Therapy Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 13. Global Peripheral T-cell lymphoma Therapy Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 14. Global Peripheral T-cell lymphoma Therapy Market Share by Region: 2024 VS 2031
Figure 15. Global Peripheral T-cell lymphoma Therapy Market Share by Players in 2024
Figure 16. Global Top Peripheral T-cell lymphoma Therapy Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peripheral T-cell lymphoma Therapy as of 2024)
Figure 17. The Top 10 and 5 Players Market Share by Peripheral T-cell lymphoma Therapy Revenue in 2024
Figure 18. North America Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 19. North America Peripheral T-cell lymphoma Therapy Market Share by Country (2020-2031)
Figure 20. United States Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 21. Canada Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Europe Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Peripheral T-cell lymphoma Therapy Market Share by Country (2020-2031)
Figure 24. Germany Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. France Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. U.K. Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Italy Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Russia Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Nordic Countries Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Asia-Pacific Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Peripheral T-cell lymphoma Therapy Market Share by Region (2020-2031)
Figure 32. China Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Japan Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. South Korea Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Southeast Asia Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. India Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Australia Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Latin America Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Peripheral T-cell lymphoma Therapy Market Share by Country (2020-2031)
Figure 40. Mexico Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Brazil Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Middle East & Africa Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Peripheral T-cell lymphoma Therapy Market Share by Country (2020-2031)
Figure 44. Turkey Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Saudi Arabia Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. UAE Peripheral T-cell lymphoma Therapy Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Antengene Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2020-2025)
Figure 48. Genor BioPharma Co., Ltd. Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2020-2025)
Figure 49. Hospira (Pfizer Inc.) Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2020-2025)
Figure 50. Dizal Pharma Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2020-2025)
Figure 51. Bristol-Myers Squibb Company Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2020-2025)
Figure 52. Sigma-Tau Pharmaceuticals, Inc. Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2020-2025)
Figure 53. Pacira Pharmaceuticals, Inc. Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2020-2025)
Figure 54. Spectrum Pharmaceuticals, Inc. Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2020-2025)
Figure 55. Celgene Corporation Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2020-2025)
Figure 56. Eisai Co., Ltd. Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2020-2025)
Figure 57. Leadiant Biosciences Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2020-2025)
Figure 58. Merck Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2020-2025)
Figure 59. Genmab AS Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2020-2025)
Figure 60. HUYABIO International Revenue Growth Rate in Peripheral T-cell lymphoma Therapy Business (2020-2025)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Choose Your Edition
Add to cart

Our team would be happy to assist you with your queries.

Contact us

About us

Accurate data, The latest market trends, And deeper research directions.

Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals

Latest reports

Useful links

Our Contacts

Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China

(+86) 159 1069 5232

sales@hengceresearch.com
hengceresearch.com

Allow cookies